Integrated Summary of Safety – Complexities, Communication and Completion

1 minute read

Case Studies

Published: January 25th, 2021

Phastar was contracted to assist a pharmaceutical company with the conversion of 16 legacy studies to SDTM (2 SDTM “Like” phase II studies, 14 Legacy Phase I studies) and with the pooling and reporting activities of their Integrated Summary of Safety (ISS) for a regulatory submission. It has been quite a challenging project but one of the most exciting due to its complexity.

Complete the form below to read the full case study

Related articles

Delivering Integrated Safety and Efficacy Analyses in Cushing Syndrome
Case Studies

Delivering Integrated Safety and Efficacy Analyses in Cushing Syndrome

October 6th, 2025 1 minute read

When faced with evolving analysis plans, minimal client infrastructure, and shifting output volumes, Phastar delivere...

Delivering a Complex ISS in Autoimmune Pulmonary Alveolar Proteinosis
Case Studies

Delivering a Complex ISS in Autoimmune Pulmonary Alveolar Proteinosis

September 26th, 2025 1 minute read

Phastar supported a sponsor in delivering a high-quality Integrated Summary of Safety (ISS) for a rare disease progra...

Delivering Integrated Efficacy and Safety Summaries in VMS
Case Studies

Delivering Integrated Efficacy and Safety Summaries in VMS

September 26th, 2025 1 minute read

Integrating efficacy and safety data across multiple studies is never simple—especially when patient-reported outcome...